This finding of IFITM3-mediated cancer stemness was demonstrated to contribute to 5’FU- and cisplatin-associated chemoresistance in four GC cell lines of varying IFITM3 expression (Figs. 2I–J, 3I–J, 4F, 6H). This evidence concerns the gene IFITM3 and gastric cancer.